Paliperidone extended-release

DRUG2 trials

Sponsors

Johnson & Johnson Pharmaceutical Research & Development, L.L.C., Johnson & Johnson Taiwan Ltd

Conditions

Bipolar DisorderMood DisordersSchizophrenia

Phase 3

A Study to Evaluate the Efficacy and Safety of Three Fixed Doses of Extended-release Paliperidone in Subjects With Bipolar I Disorder

CompletedNCT00299715

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Bipolar Disorder, Mood Disorders

Start: 2006-02-28End: 2007-06-30Updated: 2011-06-09

Phase 4

A Study to Evaluate the Effect of Oral Paliperidone Extended-Release and Oral Risperidone Immediate-Release on Cognitive Function in Clinically Stable Patients With Schizophrenia

TerminatedNCT01670071

Johnson & Johnson Taiwan LtdSchizophrenia

Start: 2013-01-31End: 2015-06-30Updated: 2016-04-13